Inclusion Criteria:

        Phase 1 a:

          -  Have histological or cytological evidence of a diagnosis of a solid tumor cancer that
             is advanced and/or metastatic

          -  Have available archived tissue for exploratory biomarker analysis

          -  Have adequate organ function

          -  Have discontinued all previous treatments for cancer and recovered from their side
             effects

          -  Are able to swallow capsules/tablets

        Phase 1 b:

          -  Cohort 1: Triple-negative breast cancer (TNBC).

          -  Cohort 2: Clear cell ovarian cancer, endometrioid ovarian cancer, or endometrioid
             endometrial carcinoma with a LOF mutation in one or more of the following genes:
             ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).

          -  Cohort 3: Soft tissue sarcoma or sarcomatoid/rhabdoid malignancy with loss of
             expression of INI1, BRG1, or BRM by immunohistochemistry or a LOF mutation in one or
             more of the following genes: ARID1A, SMARCA2, SMARCA4, or SMARCB1. Participants aged ≥
             12 years with a body weight of ≥ 40 kilogram (kg) are acceptable for Cohorts 3.
             Participants with synovial sarcoma and a confirmed SS18-SSX gene fusion are also
             eligible.

          -  Cohort 4: Epithelioid sarcoma with INI1 loss of expression by immunohistochemistry or
             SMARCB1 LOF mutation. Participants aged ≥ 12 years with a body weight of ≥ 40 kilogram
             (kg) are acceptable for Cohorts 4.

          -  Cohort 5: Bladder cancer with a LOF mutation in one or more of the following genes:
             ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).

        Exclusion Criteria:

          -  Have symptomatic central nervous system (CNS) malignancy or metastasis

          -  Have symptomatic human immunodeficiency virus (HIV), Hepatitis A, B, or C

          -  Have congestive heart failure

          -  Are breastfeeding